WOBURN, Mass. (Aug. 20, 2019) – ROMEG Therapeutics, an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the United States Patent and Trademark Office has issued two additional U.S. patents that are directed to the formulation, methods of use and administration of ROMEG’s proprietary colchicine oral solution, which will be marketed as GLOPERBA® and is currently indicated for prophylaxis of gout flares in adults.
U.S. patent numbers 10,383,820 and 10,383,821 are the third and fourth patents ROMEG has been granted for its colchicine oral solution and will join the first two patents already listed in the U.S. Food and Drug Administration’s Orange Book, the guide to drugs classified by the agency as safe and effective and that are protected by a patent. Specifically, the two patents will broaden the composition claims of the colchicine oral solutions and cover methods to potentially enable additional indications.
“We are extremely pleased with the continued development of our patent portfolio, as it reflects our strategy to broaden and diversify our intellectual property,” said Naomi Vishnupad, Ph.D., ROMEG’s Chief Scientific Officer and a partner in the company. “In this case, we believe our product technology offers a novel and potentially superior treatment option for diseases such as gout and other diseases that represent significant unmet medical needs and a large market opportunity.”
GLOPERBA®, approved by the FDA earlier this year, was recently licensed to Avion Pharmaceuticals, LLC of Alpharetta, Ga., for exclusive commercialization within the United States. The current U.S. market for gout is about $650 million annually.
About ROMEG Therapeutics
ROMEG Therapeutics, LLC, is a privately held specialty pharmaceutical company based in Woburn, Mass. The company’s mission is to develop new FDA-approved therapies by formulating novel dosage forms, improving the design and function of existing approved drugs, and expanding clinical indications for use of those drugs, thereby bringing greater value to earlier scientific discovery. The company is focused on developing a broad intellectual property portfolio to offer novel therapies to provide patients and physicians better treatment options. For more information, visit www.romegrx.com.